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Introduction Androgens have been hypothesised to influence
risk of breast cancer through several possible mechanisms,
including their conversion to estradiol or their binding to the
oestrogen receptor and/or androgen receptor (AR) in the
breast. Here, we report on the results of a large and
comprehensive study of the association between genetic
variation in the AR gene and risk of breast cancer in the National
Cancer Institute Breast and Prostate Cancer Cohort
Consortium (BPC3).
Methods The underlying genetic variation was determined by
first sequencing the coding regions of the AR gene in a panel of
95 advanced breast cancer cases. Second, a dense set of
markers from the public database was genotyped in a panel of
349 healthy women. The linkage disequilibrium relationships
(blocks) across the gene were then identified, and haplotype-
tagging single nucleotide polymorphisms (htSNPs) were
selected to capture the common genetic variation across the
locus. The htSNPs were then genotyped in the nested breast
cancer cases and controls from the Cancer Prevention Study II,
European Prospective Investigation into Cancer and Nutrition,
Multiethnic Cohort, Nurses' Health Study, and Women's Health
Study cohorts (5,603 breast cancer cases and 7,480 controls).
Results We found no association between any genetic variation
(SNP, haplotype, or the exon 1 CAG repeat) in the AR gene and
risk of breast cancer, nor were any statistical interactions with
known breast cancer risk factors observed.
Conclusion Among postmenopausal Caucasian women,
common variants of the AR gene are not associated with risk of
breast cancer.
Introduction
The effects of testosterone activity in the breast are still
unknown, showing both proliferative and anti-proliferative
effects in vitro [1-3]. Levels of testosterone, which is produced
in the ovaries, adrenal gland, and peripherally in adipose tis-
sue, either change little or decline slightly after menopause [4-
9]. In both pre- and postmenopausal women, circulating testo-
sterone levels are associated with increased risk of breast can-
cer [10-17].
The androgen receptor (AR) protein exists as two isoforms,
both arising from the same DNA sequence on the X chromo-
some (Xq11-q12). The shorter form of the AR protein lacks the
N-terminal region, which is coded by exon 1. Within exon 1 is
a tri-nucleotide CAG repeat. Although this polymorphism is
associated with AR transactivation activity [18-21] and pros-
tate cancer risk in some studies [22-28], no clear association
has been shown with breast cancer risk [29-34]. The 3' UTR
(untranslated region) of the AR contains sequence elements
that bind to proteins involved in regulation of mRNA stability.
This and other sequence-specific characteristics of AR
mRNA, including putative function of the repeats in exon 1,
have recently been reviewed [35]. The AR is expressed in the
normal breast, as well as in primary and metastatic breast can-
cer tumours, and both the expression and protein levels are
correlated with tumour invasiveness [36].
We hypothesised that inherited polymorphisms in genes
related to sex steroid hormone synthesis, metabolism, and cell
signaling could alter the function of these genes and the pro-
teins they encode, therefore altering breast cancer risk; in this
report, we present results for the AR. We used a haplotype-
tagging approach, which aims to capture common variants in
the AR gene. Here, we present these haplotypes and describe
their association with breast cancer risk in a pooled analysis of
nested case control studies from a large collaborative study,
the Breast and Prostate Cancer Cohort Consortium (BPC3)




The BPC3 has been described in detail elsewhere [37].
Briefly, the consortium includes five large well-established
cohorts assembled in the U.S. and Europe which have both
DNA samples and extensive questionnaire information (the
American Cancer Society Cancer Prevention Study II [38], the
European Prospective Investigation into Cancer and Nutrition
[EPIC] cohort [39], the Harvard Nurses' Health Study [NHS]
[40] and Women's Health Study [WHS] [41], and the Hawaii-
Los Angeles Multiethnic Cohort [MEC] [42]). Most women in
these cohorts, with the exception of the MEC, were Cauca-
sians of U.S. and European descent. Breast cancer cases
were identified in each cohort by self-report with subsequent
confirmation of the diagnosis from medical records or tumour
registries and/or from linkage with population-based tumour
registries (method of confirmation varied by cohort). Controls
were matched to cases by ethnicity and age and, in some
cohorts, additional criteria (such as country of residence in
EPIC).
Genotyping
Coding regions of AR were sequenced in a panel of 95
advanced breast cancer cases from the MEC (19 of each eth-
nic group: African-American, Latino, Japanese, Native Hawai-
ian, and white). Thirty-two single nucleotide polymorphisms
(SNPs) with minor allele frequency greater than 5% in any of
the five ethnic groups or greater than 1% overall were selected
from this resequencing as well as any SNP available in dbSNP
to be used to select haplotype-tagging SNPs (htSNPs). These
SNPs were genotyped in a reference panel of 349 healthy
women from the MEC populations (including 70 whites) at the
Broad Institute (Cambridge, MA, USA) using the Sequenom,Page 2 of 9
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USA) platforms, and six htSNPs were selected to maximise
R2H (a measure of correlation between SNPs genotyped and
the haplotypes they describe) among Caucasians, using the
method of Stram et al. [43]. Genotyping of the six htSNPs in
the breast cancer cases and controls was performed in three
laboratories (University of Southern California, Los Angeles,
CA, USA; Harvard School of Public Health, Boston, MA, USA;
and International Agency for Research on Cancer, Lyon,
France) using a fluorescent 5' endonuclease assay and the
ABI-PRISM 7900 for sequence detection (Taqman) (Applied
Biosystems, Foster City, CA). Initial quality control checks of
the SNP assays were performed at the manufacturer (Applied
Biosystems); an additional 500 test reactions were run by the
BPC3. Assay characteristics for the six htSNPs for AR are
available on a public website [44]. Sequence validation for
each SNP assay was performed and 100% concordance was
observed [45]. To assess inter-laboratory variation, each gen-
otyping centre ran assays on a designated set of 94 samples
from the Coriell Biorepository (Camden, NJ, USA), showing
completion and concordance rates of greater than 99% [45].
The internal quality of genotype data at each genotyping cen-
tre was assessed by typing 5%–10% blinded samples in
duplicate or triplicate (depending on the study); the resulting
concordance was greater than 99%. The genotyping success
rate was 94% or greater for each of the six SNPs at each gen-
otyping centre. No deviation from Hardy-Weinberg equilibrium
was observed among the controls in each cohort (at the p <
0.01 level) for any given assay. An association among the exon
1 CAG repeat in AR, family history of breast cancer, and
breast cancer risk was previously reported (1990–96 follow-
up in the NHS, 617 cases and 960 controls [46]). The exon 1
CAG repeat was genotyped in an additional 376 cases and
540 controls from the NHS as well as 669 cases and 674
controls from the WHS, as previously described [46]. Given
that there is no association between the CAG repeat and
breast cancer risk, and the interaction between this polymor-
phism and family history was not observed in this larger com-
bined sample set (1,662 cases and 2,174 controls), we
decided not to expend the resources necessary to genotype
the repeat in the remaining data sets.
Statistical analysis
We used conditional multivariate logistic regression to esti-
mate odds ratios (ORs) for disease in subjects with a linear
(additive) scoring for zero, one, or two copies of the minor
allele of each SNP. We also used conditional logistic regres-
sion with additive scoring and the most common haplotype as
the referent to estimate haplotype-specific ORs, using an
expectation-substitution approach to assign haplotypes based
on the unphased genotype data and to account for uncertainty
in assignment [47,48]. Haplotype frequencies and expected
subject-specific haplotype indicators were calculated sepa-
rately for each cohort (as well as by country within EPIC and
race in the MEC). To test the global null hypothesis of no asso-
ciation between variation in AR haplotypes and htSNPs and
risk of breast cancer (or subtypes defined by receptor status),
we used a likelihood ratio test comparing a model with additive
effects for each common haplotype (treating the most com-
mon haplotype as the referent) to the intercept-only model. We
combined rare haplotypes (those with estimated individual fre-
quencies less than 5% in all cohorts) into a single category
that comprised less than 1.5% of the controls.
We considered both unadjusted conditional models and con-
ditional models adjusting for known breast cancer risk factors.
The covariates included to account for breast cancer risk fac-
tors were age at menarche (≤12 years, 13–14 years, 15+
years), menopausal status (pre-, peri-, and postmenopausal),
parity (ever/never full-term pregnancy), body mass index (BMI)
(in kg/m2 as a continuous variable), and use of postmenopau-
sal hormones (ever/never). Other common risk factors, includ-
ing family history of breast cancer, personal history of benign
breast disease, and age at menopause, were unavailable for
large numbers of women and therefore were not included in
the models. Because the results remained essentially
unchanged regardless of the model used, we present results
using the unadjusted conditional model. We also evaluated
these covariates, restricting analyses of interaction to only
those subjects with information available for variables such as
family history, with categorical variables divided into quintiles.
Interaction effects were evaluated using likelihood ratio test-
ing, comparing models with the main effects of the genetic and
risk variable to the model with these main effects and a multi-
plicative interaction term. Lastly, we tested whether the asso-
ciation between AR and breast cancer differed by menopausal
status at diagnosis and tumour receptor (oestrogen receptor
[ER] and progesterone receptor [PR]) status.
The exon 1 CAG repeat was analysed as previously reported
[44]. Interaction p values between number of repeats and fam-
ily history were calculated using likelihood ratio tests compar-
ing the model with main effects for carrying at least one long
repeat (cutoffs of ≥22, 23, 25, and 27 repeats) and family his-
tory with the model containing these main effects, and an addi-
tional interaction term, with homozyotes of the ≥22 allele with
no family history as the reference.
Results
Figure 1 shows the genomic structure of the region around
AR. One very common (approximately 70%) haplotype exists,
with six lower-prevalence haplotypes being defined each by
the htSNPs. The minimum R2H for these six SNPs was 0.77 in
the Japanese, white, and Latina samples from the SNP selec-
tion panel. However, these SNPs do not describe haplotype
diversity among African-Americans (minimum R2H = 0.03).
A total of 5,603 cases and 7,480 controls were available for
genotyping. Table 1 shows some of the baseline characteris-
tics of these cases and controls. Genotyping success for eachPage 3 of 9
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ing a genotype for a given SNP were removed from analyses
for that SNP. Samples not yielding at least one genotype were
removed from haplotype analyses, for a total of 5,584 cases
and 7,459 controls. No associations with breast cancer or het-
erogeneity of risk estimates across the participating cohorts
were observed for any individual SNP (Table 2) or haplotype
tagged by these SNPs (Table 3). No differences in haplotype
distribution were observed between ER+ (n = 2,543) and ER-
(n = 590) cases (global p value = 0.61), PR+ (n = 2,158) and
PR- (n = 860) cases (global p value = 0.51), or localised (n =
2,964) and metastatic (n = 1,646) cases (global p value =
0.43). No statistically significant interactions were observed
between haplotypes and common breast cancer risk factors
such as family history (yes/no), BMI (≤25, >25), age at first full-
term pregnancy (nulliparous, ≤24, >24), or alcohol consump-
tion (non-drinkers, ≤5 g/day, >5 g/day) (p interaction = 0.13,
0.16, 0.14, and 0.28, respectively). These results were not
materially different after excluding African-American women
from the MEC (344 cases and 426 controls).
Data from further follow-up of the NHS and the WHS did not
support the previous findings of interaction between the AR
CAG repeat and family history on breast cancer risk in the
NHS with follow-up to 1996 [46]. No statistically significant
interactions between longer AR CAG repeat length and posi-
tive family history were observed in either the further NHS fol-
low-up or the WHS. The decrease in risk associated with
shorter repeats among family history positive cases as previ-
ously reported [46] was not observed (Table 4).
Discussion
One of the main aims of the BPC3 was to overcome limitations
of prior studies by increasing sample size and, therefore,
power of the study. By choosing genes involved in the synthe-
sis, metabolism, and signaling of sex hormones, we aimed to
maximise the possibility of finding alleles that predispose to
breast cancer. Although the AR gene is a likely candidate
gene, no association between polymorphisms in the AR gene
and breast cancer risk was observed, despite the large sample
size (5,603 cases and 7,480 controls) and systematic
approach of this study.
Figure 1
Linkage disequilibrium (LD) at androgen receptor (AR). Linkage disequilibrium plot generated by Haploview [50] showing correlation between all 
pairs of single nucleotide polymorphisms (SNPs) genotyped to select haplotype-tagging SNPs (ht-SNPs). The 32 SNPs genotyped among the 349 
Multiethnic Cohort samples are shown in their physical position along the X chromosome (solid black horizontal line) and relative to the AR gene 
(depicted above the X chromosome plot). htSNPs selected are shown by arrows. Although two LD blocks are shown (black outline in LD plot), high 
correlation between the blocks allowed for the analysis of the htSNPs as one block.Page 4 of 9
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Baseline characteristics of BPC3 participants by cohort
ACS EPIC MEC NHS WHS All
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
Number 503 505 1,719 2,844 1,617 1,962 1,059 1,464 705 705 5,603 7,480
Mean age in years at blood 
donation (standard deviation)
68.9 (5.9) 68.9 (5.8) 55.4 (7.9) 55.1 (8.3) 66.4 (8.6) 63.6 (8.7) 57.6 (7.0) 58.2 (6.9) 56.0 (7.3) 56.0 (7.3) 60.2 (9.4) 59.0 (9.0)
Mean body mass index 
(standard deviation)
25.2 (4.6) 25.5 (4.6) 25.9 (4.4) 26.1 (4.6) 26.7 (5.6) 27.0 (6.0) 25.4 (4.7) 25.6 (4.7) 25.5 (4.4) 26.0 (5.1) 25.9 (4.9) 26.2 (5.1)
Age in years at menarche
≤12 46.9 45.3 35.5 36.2 53.9 49.7 42.4 48.7 56.7 51.6 47.8 44.3
13–14 43.9 46.7 48.5 45.5 35.5 38.6 39.5 42.9 37.0 42.7 41.1 43.0
15+ 9.3 8.0 16.0 18.4 10.5 11.7 8.1 8.4 6.2 5.7 11.0 12.7
Menopausal status
Premenopausal 0 0 24.3 27.7 11.0 16.5 19.4 16.9 21.7 21.2 17.0 20.2
Postmenopausal 100 100 67.1 63.6 86.5 81.8 71.3 74.8 63.5 60.2 76.0 72.7
Perimenopausal/unknown 0 0 8.6 8.7 2.5 1.7 9.4 8.3 14.8 18.6 7.0 7.1
Age in years at menopause*
<40 10.2 9.9 4.5 5.0 16.3 18.9 9.9 11.1 7.1 9.0 10.6 11.4
40–44 10.2 12.4 9.5 10.3 14.9 16.9 12.2 11.3 10.0 14.5 12.0 13.1
45–49 20.4 28.2 28.9 31.8 26.6 27.9 27.6 28.1 31.1 31.6 27.0 29.4
50–54 46.6 39.7 47.1 44.0 32.8 29.0 44.5 43.7 43.9 36.8 41.3 38.4
55+ 12.6 9.9 10.0 8.9 9.4 7.3 5.8 5.8 7.8 8.0 9.1 7.8
Parous women 91.0 91.4 86.7 86.8 85.5 88.8 92.3 93.3 84.8 86.2 87.5 88.9
Family history 20.7 15.5 - - 17.1 11.1 19.2 13.9 20.1 16.3 18.6 13.3
Ever HRT use* 67.0 58.7 42.3 34.1 63.9 58.9 77.2 72.0 68.0 60.3 61.4 53.5
Carcinoma in situ 21.5 - 6.3 - 1.0 - 0 - 0 - 4.1 -
ER-positive 52.7 - - - 62.0 - 68.0 - 80.4 - 65.8 -
PR-positive 44.5 - - - 51.1 - 57.5 - 71.9 - 55.8 -
Ethnicity
White 97.8 98.6 100 100 24.8 22.4 93.6 93.6 95.6 95.6 76.3 77.9
Hispanic 0.8 0.2 0 0 20.8 19.7 0.1 0.3 0.6 0.6 6.2 5.3
African-American 0.8 0.8 0 0 21.3 21.7 0.8 0.6 0.7 0.7 6.5 5.9
Asian 0.4 0.4 0 0 26.3 21.4 0.1 0.4 1.0 1.0 7.8 5.8
Hawaiian 0 0 0 0 6.7 14.8 0 0 0 0 2.0 3.9
Other 0.2 0 0 0 0 0 5.5 5.1 2.1 2.1 1.3 1.2Page 5 of 9
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ymorphism in exon 1 of the AR gene were associated with
decreased risk of disease in women with a family history of
breast cancer in the NHS. Adding samples from further follow-
up cycles of the NHS, as well as samples from the WHS, we
were unable to confirm this initial finding.
Mutations in genes such as BRCA1 (breast cancer 1, early
onset) and BRCA2, although highly penetrant, are of low prev-
alence in the general population. Very few common polymor-
phisms have been shown to be associated with breast cancer
risk. Using a candidate gene approach to select genes of pos-
sible interest in breast cancer etiology has also yielded very
few breast cancer-susceptibility loci. One possible explanation
for the lack of consistent association between common poly-
morphisms and breast cancer risk in individual studies is that
the change in risk associated with common variants is too low
to detect in individual studies and results that are reported may
reflect publication bias.
The 95% confidence intervals in our study were narrow and
exclude a substantial association between common variants in
the AR gene with breast cancer risk. A concern that is more
specific to the AR gene is that, due to the gene's location on
the X chromosome, X chromosome inactivation could bias risk
estimates associated with a causal allele toward the null. Such
bias would be especially likely if the same X chromosome
(either maternal or paternal) were inactivated in all breast tis-
sue within each woman. However, X chromosome inactivation
occurs very early in embryonic development and differs
between lobes within the same breast [49]. Assuming a low-
penetrance allele (as hypothesised here), women who are het-
erozygous for a putative risk allele on the X chromosome are
still at approximately half the risk of developing breast cancer
as women who are homozygous for the same allele, as approx-
ACS, American Cancer Society; BPC3, Breast and Prostate Cancer Cohort Consortium; EPIC, European Prospective Investigation into Cancer 
and Nutrition; ER, oestrogen receptor; HRT, hormone replacement therapy; MEC, Multiethnic Cohort; NHS, Nurses' Health Study; PR, 
progesterone receptor; WHS, Women's Health Study.
* Among post-menopausal women only
Table 2
Association between breast cancer and individual htSNPs in the AR across the BPC3 cohorts
SNP Genotype Cases (percentage)a Controls (percentage)a OR (95% CI)b P trendc P heterogeneityd
AR_001 AA 4,480 (82) 6,034 (83) 1.00 (Ref.) . .
rs962458 AG 826 (15) 1,054 (14) 1.04 (0.95 to 1.15) . .
GG 146 (3) 187 (3) 1.02 (0.83 to 1.26) 0.50 0.96
AR_002 GG 3,833 (71) 5,073 (70) 1.00 (Ref.) . .
rs6152 GA 1,324 (25) 1,815 (25) 0.98 (0.90 to 1.06) . .
AA 245 (5) 314 (4) 1.02 (0.87 to 1.20) 0.89 0.84
AR_003 GG 3,773 (70) 4,984 (69) 1.00 (Ref.) . .
rs1204038 GA 1,279 (24) 1,762 (24) 0.97 (0.90 to 1.06) . .
AA 365 (7) 452 (6) 1.05 (0.89 to 1.23) 0.96 0.86
AR_004 AA 4,940 (90) 6,540 (90) 1.00 (Ref.) . .
rs2361634 AG 524 (9) 727 (10) 0.95 (0.85 to 1.07) . .
GG 25 (<1) 24 (<1) 1.30 (0.76 to 2.21) 0.70 0.56
AR_005 AA 4,601 (84) 6,188 (85) 1.00 (Ref.) . .
rs1337080 AG 802 (15) 1,012 (14) 1.07 (0.97 to 1.18) . .
GG 65 (1) 81 (1) 1.06 (0.80 to 1.41) 0.20 0.88
AR_006 AA 3,442 (63) 4,596 (63) 1.00 (Ref.) . .
rs1337082 AG 1,601 (29) 2,154 (29) 1.01 (0.94 to 1.09) . .
GG 416 (8) 556 (8) 0.99 (0.85 to 1.14) 0.97 0.29
aNumbers of cases and controls genotyped for each SNP vary due to assay failure; bunadjusted logistic regression, conditional on matching factors 
and cohort as described in text; ctest for trend for log-additive or codominant model; dtest for heterogeneity in ORs across cohorts. AR, androgen 
receptor; BPC3, Breast and Prostate Cancer Cohort Consortium; CI, confidence interval; htSNP, haplotype-tagging single nucleotide 
polymorphism; OR, odds ratio; Ref., Reference category; SNP, single nucleotide polymorphism.
Table 1 (Continued)
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would not express or be exposed to the risk allele, compared
with all breast cells expressing the risk allele among
homozygotes. This somewhat limits the possibility that X chro-
mosome inactivation patterns could bias risk estimates toward
the null. Optimally, tumour tissue from heterozygous women
would be analysed to determine which allele is inactivated;
however, this is not possible in the present study, because
tumour specimens are not available.
Due to the low numbers of premenopausal women in our
study, we cannot exclude the AR gene as a susceptibility
locus for breast cancer occurring before menopause. Addi-
tionally, although the MEC does provide information from non-
Caucasian individuals, there are not a sufficient number of
samples, and htSNPs selected to describe genetic variation in
Caucasians is not sufficient among African-Americans to
definitively exclude polymorphisms in the AR gene as breast
cancer-susceptibility alleles except in Caucasians. Among the
Table 3
Association between AR haplotypes and breast cancer risk in the NCI BPC3
Haplotype Percentage in cases (n = 5,584) Percentage in controls (n = 7,459) ORa (95% CI)
AGGAAA 0.72 0.71 1.00 (Ref.)
GAAAGG 0.08 0.08 1.01 (0.93 to 1.11)
AAAAAG 0.06 0.07 0.94 (0.85 to 1.03)
AGGGAA 0.05 0.05 0.97 (0.87 to 1.08)
AGGAAG 0.05 0.05 1.02 (0.91 to 1.15)
GAAAAG 0.02 0.02 0.99 (0.83 to 1.18)
AGAAAG 0.02 0.01 0.98 (0.82 to 1.18)
<5% 0.02 0.01 1.18 (0.98 to 1.43)
aUnadjusted logistic regression, conditional on matching factors and cohort as described in text. AR, androgen receptor; CI, confidence interval; 
NCI BPC3, National Cancer Institute Breast and Prostate Cancer Cohort Consortium; OR, odds ratio; Ref., Reference category.
Table 4
AR exon 1 CAG Repeat length and family history in the NHS and the WHS
Family history Genotypea [CAG]n 1990–1996 OR (95% CI)b 1998–2000 OR (95% CI)b WHS OR (95% CI)b NHS and WHS Combined OR 
(95% CI)b
no <22 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.)
no ≥22 0.9 (0.8 to 1.2) 1.0 (0.7 to 1.4) 0.7 (0.5 to 1.0) 1.0 (0.9 to 1.2)
yes <22 1.0 (0.6 to 1.7) 2.0 (0.9 to 4.2) 1.6 (0.8 to 3.0) 1.1 (0.9 to 1.5)
yes ≥22 1.7 (1.2 to 2.4) 1.6 (0.9 to 2.6) 1.1 (0.7 to 1.8) 1.3 (1.1 to 1.6)
no <22 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.)
no ≥23 0.9 (0.7 to1.2) 0.9 (0.7 to 1.3) 0.7 (0.5 to 1.0) 1.0 (0.9 to 1.2)
yes <22 1.0 (0.8 to 1.4) 1.9 (0.9 to 4.1) 1.6 (0.8 to 3.0) 1.1 (0.9 to 1.5)
yes ≥23 1.8 (1.2 to 2.5) 1.5 (0.9 to 2.6) 1.0 (0.6 to 1.5) 1.4 (1.1 to 1.8)
no <22 1.00 (Ref.) 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.)
no ≥25 1.0 (0.8 to 1.4) 0.9 (0.6 to 1.3) 0.7 (0.5 to 1.1) 1.0 (0.9 to 1.2)
yes <22 1.1 (0.6 to 1.8) 1.8 (0.9 to 4.0) 1.6 (0.8 to 3.0) 1.1 (0.9 to 1.5)
yes ≥25 2.0 (1.3 to 3.1) 1.5 (0.7 to 3.0) 0.7 (0.4 to 1.3) 1.5 (1.1 to 2.0)
no <22 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.)
no ≥27 1.1 (0.7 to 1.7) 1.4 (0.8 to 2.5) 0.8 (0.5 to 1.3) 1.1 (0.9 to 1.4)
yes <22 1.1 (0.6 to 1.9) 2.0 (0.9 to 4.6) 1.6 (0.8 to 3.0) 1.1 (0.9 to 1.6)
yes ≥27 1.6 (0.8 to 3.1) 2.1 (0.7 to 6.5) 0.7 (0.3 to 1.8) 1.4 (0.9 to 2.1)
aAR genotype defined as having one or more long alleles ≥22, 23, 25, or 27 versus both alleles <22; bunconditional, unadjusted logistic regression. 
AR, androgen receptor; CI, confidence interval; NHS, Nurses' Health Study; OR, odds ratio; Ref., Reference category; WHS, Women's Health 
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of the AR gene is associated with risk of postmenopausal
breast cancer.
Conclusion
Common polymorphisms in the AR gene are not associated
with breast cancer risk among postmenopausal Caucasian
women.
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